Posted by SLS on December 6, 2010, at 5:48:23
In reply to Seroquel for unipolar depression, posted by sk85 on December 5, 2010, at 12:24:03
> Maybe this has been asked before.
> I'm suffering from unipolar depression and wondering if Seroquel as a monotheraphy would be of help. Can anyone share their experiences with Seroquel as a mood booster? What was the dose and did it matter a lot?Seroquel has been studied only recently for use in unipolar depression.
- Scott
---------------------------------------
Journal of Affective Disorders
Volume 127, Issues 1-3, December 2010, Pages 19-30
doi:10.1016/j.jad.2010.08.032 | How to Cite or Link Using DOI
Copyright © 2010 Elsevier B.V. All rights reserved.
Permissions & Reprints
Review
A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorderAlert
This article is not included in your organization's subscription. However, you may be able to access this article under your organization's agreement with Elsevier.Michael Bauera, low asterisk, E-mail The Corresponding Author, Nizar El-Khalilib, Catherine Dattoc, Johan Szamosid and Hans Erikssond
a Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, D-01307 0 Dresden, Germany
b Alpine Clinic, Lafayette, IN, USA
c AstraZeneca Pharmaceuticals, Wilmington, DE, USA
d AstraZeneca R&D, Södertälje, Sweden
Received 24 September 2009;
revised 26 August 2010;
accepted 26 August 2010.
Available online 29 September 2010.Abstract
BackgroundTwo positive studies evaluated adjunctive extended release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder (MDD) showing inadequate response to antidepressant treatment. This preplanned, pooled analysis provides an opportunity for subgroup analyses investigating the influence of demographic and disease-related factors on observed responses. Additional post hoc analyses examined the efficacy of quetiapine XR against specific depressive symptoms including sleep.
MethodsData were analysed from two 6-week, multicentre, double-blind, randomised, placebo-controlled studies, prospectively designed to be pooled. Patients received once-daily quetiapine XR 150 mg/day (n = 309), 300 mg/day (n = 307) or placebo (n = 303) adjunctive to ongoing antidepressant therapy. The primary endpoint was change from randomisation to Week 6 in MADRS total score. Other assessments included MADRS response (≥ 50% decrease in total score) and remission (total score ≤ 8), change from randomisation in HAM-D, HAM-A, PSQI global and CGI-S scores.
ResultsQuetiapine XR (150 and 300 mg/day) reduced MADRS total scores vs placebo at every assessment including Week 6 (− 14.5, − 14.8, − 12.0; p < 0.001 each dose) and Week 1 (− 7.8,−7.3,−5.1; p < 0.001 each dose). For quetiapine XR 150 and 300 mg/day and placebo, respectively at Week 6: MADRS response 53.7% (p = 0.063), 58.3% (p < 0.01) and 46.2%; MADRS remission 35.6% (p < 0.01), 36.5% (p < 0.001) and 24.1%. Quetiapine XR 150 and 300 mg/day significantly improved HAM-D, HAM-A, PSQI and CGI-S scores at Week 6 vs placebo. Quetiapine XR demonstrated broad efficacy, independent of factors including concomitant antidepressant.
LimitationsFixed dosing; lack of active comparator.
ConclusionsAdjunctive quetiapine XR is effective in patients with MDD and an inadequate response to antidepressant therapy, with improvement in depressive symptoms seen as early as Week 1.
Keywords: Extended release; Quetiapine; Adjunctive; Major depressive disorder
Article Outline
Some see things as they are and ask why.
I dream of things that never were and ask why not.
poster:SLS
thread:972589
URL: http://www.dr-bob.org/babble/20101203/msgs/972667.html